[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hallucinations-auditory\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hallucinations-auditory":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,81,106,128,151,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100423765","fmri-based-neurofeedback-to-relieve-drug-resistant-auditory-hallucinations-100423765",false,"NCT04798131","fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations","Treat Refractory Auditory Hallucinations in Schizophrenia Patients With fMRI-guided Neurofeedback: a Randomized-controlled Trial","INTRUDE","Inclusion Criteria:\n\n* Schizophrenia (according to the DSM-5 classification)\n* Frequent auditory hallucinations (SAPS item #1 ≥ 4)\n* Stable medication for at least 30 days\n* Absence of chronic neurological disorder (including seizure)\n* Able to provide free written consent to participate in the research\n\nExclusion Criteria:\n\n* Pregnancy\n* Contraindication to MRI scan\n* Claustrophobia\n* No social insurance","ALL","18 Years","60 Years",{"count":21,"type":22},84,"ESTIMATED","INTERVENTIONAL",[25],"NA","The INTRUDE trial aims at assessing the efficacy of an fMRI-based neurofeedback procedure on drug-resistant auditory hallucinations. Hallucinations are complex and transient mental states associated with subtle and brain-wide patterns of activity for which we were recently able to validate an fMRI multivariate decoder. Based on this progress, we can track patients' hallucinatory status using real-time fMRI. We will test whether schizophrenia patients with drug-resistant hallucinations can be trained to maintain the brain state associated with a no-hallucination condition using appropriate strategies and thus reduce overall severity. We will refer to a double-blind randomized placebo-controlled design. A total of 86 patients will be enrolled and equally split in an active neurofeedback group (n=43) and a sham group (n=43), matched for sex, age and PANSS scores. Each patient will benefit from 4 runs of either active or sham neurofeedback. The primary outcome measure will be the mean decrease of AHRS scores relative to baseline, and at 1 month post-treatment. We expect significant clinical benefits from fMRI-based neurofeedback on drug-resistant hallucinations compared with the sham group.",[28,29,30],"Schizophrenia","Hallucinations, Auditory","Hallucinations, Visual",[28,32,33,34,35,36],"Hallucinations","Drug-resistance","functional MRI","Neurofeedback","Machine-Learning.","RECRUITING","2026-05-14",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":43,"type":41},"2022-08-26",{"date":45,"type":22},"2026-07",{"name":47,"class":48},"University Hospital, Lille","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100635637","testing-a-peer-support-group-for-veterans-who-hear-voices-100635637","NCT07555275","Testing a Peer-Support Group for Veterans Who Hear Voices","A Multisited Efficacy Trial of Veteran Voices and Visions","VVV RCT","Inclusion Criteria:\n\n* Has been experiencing auditory hallucinations at least weekly within the past 6 months that are not exclusively due to substance use\n* English fluency sufficient for participating in groups\n* Able to provide consent\n\nExclusion Criteria:\n\n* Psychosis exclusively due to substance use\n* Clinically significant seizure disorder, traumatic brain injury, dementia, developmental disorder\u002Fintellectual disability\n* Inability to provide informed consent for any reason, including due to acute psychosis, mania, or dementia, or active guardianship or durable power of attorney\n* Plan to transfer or terminate care in the next 3 months\n* Has previously attended a VVV group",{"count":59,"type":22},160,[25],"Veterans with schizophrenia spectrum disorders who experience psychosis struggle with social integration- e.g., participation in work, housing, and citizenship-due to symptoms, stigma, and psychosocial functioning deficits. Veteran Voices and Visions (VVV) is a psychosocial, peer-led group intervention for Veterans with psychosis based that reduces distress related to psychosis and fosters a sense of belonging for Veterans living with psychosis. VVV destigmatizes psychosis; reframes symptoms; and introduces personalized, meaningful coping strategies enabling social interaction. The investigators will assess VVV's efficacy in a trial comparing recipients of VVV to another peer-led group, Wellness Recovery Action Planning (WRAP), on outcomes of distress from psychosis, sense of belonging, and social functioning while identifying contextual factors regarding implementation at two sites. The investigators hypothesize that proximal reduction in distress and increased sense of belonging results in improvements in social functioning.",[63,29,64],"Psychotic Disorders","Social Isolation",[63,66,67,68],"hallucinations, auditory","social isolation","Veterans","NOT_YET_RECRUITING","2026-04-21",{"date":72,"type":41},"2026-04-29",{"date":74,"type":22},"2027-04-01",{"date":76,"type":22},"2030-09-30",{"name":78,"class":79},"VA Office of Research and Development","FED",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":49},"100617122","the-echo-study-compassion-focused-therapy-for-young-voice-hearers-and-their-caregivers-100617122","NCT07314515","The ECHO Study: Compassion-focused Therapy for Young Voice Hearers and Their Caregivers","ECHO","Inclusion Criteria:\n\n* The participants should have been referred to a child and adolescent psychiatric hospital in Denmark .\n* The participants have heard voices within the last 2 weeks.\n* The participant can hear the content of the voices. The content takes the form of spoken works.\n* A caregiver who can participate in 5 sessions\n\nExclusion Criteria:\n\n* Participants has an estimated IQ under 70\n* Participants who don't speak and understand Danish,\n* Current drug misuse \u002F abuse (during sessions)\n* Brain injury or neurological disorder e.g. severe epilepsy\n* Impaired vision or hearing to a degree that makes participation in therapy under normal conditions impossible.","13 Years","21 Years",{"count":91,"type":22},80,[25],"In this project, a 10-session treatment program was developed aimed at young people who experience voice hearing. The treatment has potential to easily be implemented in everyday clinical practice in Child and Adolescent Psychiatry, and eventually in Educational Psychological Counselling (PPR) and the newly established STIME services (low-threshold municipal treatment offers for children and young people).\n\nAs part of the treatment, the young person's caregivers are involved. This means a high degree of involvement from adults who know the young person well and are part of their daily life.\n\nIn addition to traditional Compassion-focuced therapy (CFT), the treatment is expanded with an intervention where an audio file is recorded with content corresponding to the adolescent's voice hearing. The parents are invited to listen to the audio file while participating in a therapy session. This will help improve the caregivers understanding of the young person's experiences and challenges.",[29],[96],"voice hearing","2026-02-23",{"date":99,"type":41},"2026-02-24",{"date":101,"type":22},"2026-06-01",{"date":103,"type":22},"2029-01",{"name":105,"class":48},"University of Southern Denmark",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":49},"100593214","role-of-inferior-colliculi-in-auditory-hallucinations-100593214","NCT07003529","Role of Inferior Colliculi in Auditory Hallucinations","Rôle Des Colliculi inférieurs Dans Les Hallucinations Auditives : étude Pilote Par Neuroimagerie","SchizoHIC","Inclusion Criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n* DSM-5 diagnosis of schizophrenic disorder (based on clinical assessment and confirmed by the MINI 7.0 interview)\n* Patient with a schizophrenic disorder lasting ≤ 20 years\n* Patient treated in a psychiatric unit as an inpatient (in non-specialized care) or outpatient or under a mandatory ambulatory psychiatric care programme\n* Clinical condition compatible with imaging based on clinical judgment\n* Ability to understand, write, and read French\n\nSpecific inclusion criteria for the group (SCZ+\u002FHA+) • Patient with a PANSS score (question P3 regarding hallucinations) ≥ 4 (corresponds to PANSS (P3) 4, 5, 6, and 7 patients) AND having experienced hallucinations in the past 15 days.\n\nSpecific inclusion criteria for the control group\n\n• Patient with a PANSS score (question P3 regarding hallucinations) = 1) AND having not experienced any hallucinations in the past 15 days.\n\nExclusion Criteria:\n\n* The patient is under safeguard of justice or state guardianship\n* Contraindications to magnetic resonance imaging, including severe claustrophobia, based on clinical judgment.\n* Congenital or acquired deafness\n* Suicide risk, based on clinical judgment\n* Patient with moderate to severe intellectual disability, based on medical records\n* Patient with moderate to severe neurocognitive disorders, based on medical records\n* Patient receiving anticholinergic therapy (biperiden-Akineton, trihexyphenidyl-Artane, tropatepine-Lepticur)\n* Patient participating in an interventional study involving a drug or medical device, or a Category 1 RIPH within 3 months prior to inclusion\n* Person under judicial protection\n* Pregnant, parturient, or breastfeeding woman\n* Person unable to express consent",{"count":115,"type":22},40,[25],"The neural basis of auditory hallucinations (AH) in patients with schizophrenia is poorly characterized. Functional imaging studies investigate either the \"state\" dimension (i.e., the measurement of changes in brain area activation at the precise moment of AH onset) or the \"trait\" dimension (i.e., the neural correlates of the propensity to hallucinate). A corollary of AH (particularly acoustic-verbal) is the activation of brain regions involved in the auditory perception of speech (auditory cortex). One theory is that patients with schizophrenia with AH may have a deficit in processing their internal speech (i.e., external attribution to internal verbal content). However, there is little clinical data on the specific role of the mesencephalic region of the inferior colliculi (IC) in the formation of these symptoms. Preliminary research has shown intense expression of dopamine D2 receptors, particularly on glutamatergic neurons in mouse ICs. Thus, ICs receive numerous inhibitory dopaminergic inputs, likely involved in signal optimization and modulation. The study authors hypothesize that AHs are the result of a defect in signal inhibition by the IC, which lose their function as perceptual filters.",[28,29],"2025-12-02",{"date":121,"type":41},"2025-12-09",{"date":123,"type":41},"2025-09-12",{"date":125,"type":22},"2026-09",{"name":127,"class":48},"Centre Hospitalier Universitaire de Nīmes",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":49},"100390637","early-phase-1-toward-a-computationally-informed-personalized-treatment-for-hallucinations-100390637","NCT04366518","Toward a Computationally-Informed, Personalized Treatment for Hallucinations","Inclusion Criteria:\n\n* Age 18-65\n* English speaking\n* Right handedness\n* Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder\n* History of auditory verbal hallucinations occurring at least weekly\n\nExclusion Criteria:\n\n* Current substance dependence or active use as determined by drug test.\n* Any neurological, medical or developmental problem that is known to impair cognition significantly\n* Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia\n* History of seizures\n* History of violence\n* History of suicide\n* Pregnancy (determined by urine pregnancy test)\n* Concurrent participation in any other intervention study\n* History of urinary retention\n* History of delirium\n* Current use of any cholinergic or anticholinergic medication\n* History of asthma, diabetes, and cardiovascular disease\n* Evidence of cardiovascular disease on EKG\n* Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)","65 Years",{"count":136,"type":22},35,[138],"EARLY_PHASE1","Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.",[29,141],"Psychosis","2025-06-04",{"date":144,"type":41},"2025-06-05",{"date":146,"type":41},"2021-07-15",{"date":148,"type":22},"2032-08",{"name":150,"class":48},"Yale University",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":17,"minAge":158,"maxAge":134,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100588253","the-effectiveness-of-combining-arvr-technology-in-virtual-clinical-auditory-hallucinations-on-the-comprehensive-auditory-hallucination-nursing-competency-of-psychiatric-nurses-100588253","NCT06938997","The Effectiveness of Combining AR\u002FVR Technology in Virtual Clinical Auditory Hallucinations on the Comprehensive Auditory Hallucination Nursing Competency of Psychiatric Nurses","Inclusion Criteria:\n\n* A psychiatric nurse who has been engaged in nursing work in a psychiatric unit for at least three months;\n* Those who were willing to participate in the study and filled out the consent form;\n* Willing to use smartphones to watch VR360 videos;\n* Willing to cooperate with the study and use 3D glasses.\n\nExclusion Criteria:\n\n* Nurses who are about to leave or be transferred out of the psychiatric ward within six months\n* Part-time nurses\n* Part-time supervisors\n* Specialist nurses.",true,"20 Years",{"count":160,"type":22},200,[25],"This study aims to develop and evaluate a Virtual Reality (VR) Auditory Hallucination Program to enhance psychiatric nurses' comprehensive care competence in managing auditory hallucinations among patients with schizophrenia. Given that 60-80% of patients on the schizophrenia spectrum experience auditory hallucinations, and many continue to do so despite medication, improving nurses' professional skills in this area is critical.\n\nThe research is conducted in two phases across four psychiatric institutions. Phase one involves the development and validation of the VR program and an OSCE (Objective Structured Clinical Examination), piloted with five participants and evaluated by psychiatric nursing experts. Phase two is a formal interventional study with 200 psychiatric nurses, using block randomization and three data collection time points.\n\nAssessment tools include five instruments measuring nurses' confidence, knowledge, attitude, empathy, immersion, and care performance related to auditory hallucinations. The study expects to strengthen nurses' ability to assess and manage auditory hallucinations effectively, and proposes the VR program as a potential tool for nursing in-service education.",[164,165,29],"Nurses","Schizophenia Disorder",[167,168,169,170],"Auditory hallucination care competence","virtual reality","schizophrenia","Objective Structured Clinical Examination","2025-05-05",{"date":173,"type":41},"2025-05-08",{"date":175,"type":22},"2025-05-01",{"date":177,"type":22},"2027-05-01",{"name":179,"class":48},"National Yang Ming Chiao Tung University",4,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":180},"100554936","vr-based-avatar-therapy-for-treatment-of-auditory-hallucinations-100554936","NCT06505564","VR-based Avatar Therapy for Treatment of Auditory Hallucinations","VR-based Avatar Therapy for Treatment of Auditory Hallucinations in Patients With Schizophrenia 2023-SUD-3446","Inclusion Criteria:\n\n* Diagnosis of schizophrenia spectrum disorder according to DSM-5,\n* Age 18 or older,\n* The fluent use of the spoken language at the site (Hungarian\u002FSpanish\u002FPolish),\n* Informed consent provided by the patient or their caregiver after being informed about the research procedure\n* Stable medication dosage for at least 4 weeks prior to recruitment,\n* Regular psychiatric follow-up,\n* Experience of auditory hallucinations for at least three months (PANSS hallucination score of at least 3 points),\n* Meeting the remission criteria described by Andreasen, except for the score related to auditory hallucinations\n\nExclusion Criteria:\n\n* Inability to identify a single dominant voice that is the subject of the intervention,\n* Lack of cooperation,\n* Intellectual disability based on medical history,\n* Regular substance abuse\n* Central nervous system injury or neurological disease that affects cognitive performance,\n* Suicidal risk\n* Aversion to virtual reality,\n* Severe visual impairment",{"count":189,"type":22},90,[25],"The primary aim of this study is to evaluate the safety and efficacy of AVATAR therapy, developed to address residual auditory hallucinations persisting despite medication in schizophrenia spectrum disorder. The intervention aims to reduce the intensity and frequency of these symptoms, as well as alleviate associated depressive and anxiety symptoms, using a virtual reality (VR)-assisted intervention developed for this purpose by the Danish company HEKA VR. The study will be a pre-post non-invasive, waiting list-controlled study, enrolling 30 patients from three clinical sites (Hungary, Spain, Poland).\n\nThe study centers around administering therapy based on VR over a 12-week period, comprising a total of 7 sessions. These sessions are conducted individually and last 50 minutes each. The psychotherapist leading the sessions adheres to a strict protocol defined by the method's developers.\n\nDuring the intervention, VR technology is used to simulate the source of distressing auditory hallucinations. The therapist facilitates coping with these experiences externalized in this way through simulated conversations, supporting the development of more adaptive responses.\n\nPatients undergo a comprehensive cross-sectional evaluation of their condition before and after the intervention, including assessments of symptom severity, quality of life, and their experience with the method. The intervention is conducted with constant monitoring for possible adverse effects.",[29,193],"Schizophrenia Spectrum and Other Psychotic Disorders",[195,196,197,198],"Virtual reality","AVATAR therapy","Auditory verbal hallucation","Schizophrenia spectrum disorder","2024-07-17",{"date":201,"type":41},"2024-07-19",{"date":203,"type":41},"2024-03-01",{"date":205,"type":22},"2025-12-31",{"name":207,"class":48},"Semmelweis University"]